Cue Biopharma, Inc. CUE

Results support potential for differentiated clinical impact for patients suffering from chronic hives and advancement to Phase 2b/3 registration enabling studyPrimary endpoint and the key secondary endpoint were met with high statistical significance and CUE-221 demonstrated an overall favorable safety profileClinically different efficacy profile observed relative to XOLAIR® (omalizumab) highlights potential for a fundamental mechanism-based biological differenceCue Biopharma to host conference

Announced recent Investigational New Drug (IND) submission to the FDA for CUE-221 in food allergy applicationsCompleted a $50 million private placement (PIPE) to further fund clinical development and the portfolio with significant potential for value-inflectionStrengthened the leadership team with the appointments of the Chief Medical Officer and Head of R&D and the Chief Financial OfficerOperating results reflected higher expenditures related to the licensing and initiation of the CUE-221 devel

Veteran biotech finance executive joins Cue to support the Company’s next phase of clinical and corporate growth as the company advances regulatory filing for food allergyBOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, today announced the appointment of James M. Ahlers as Chief Financial Officer. Mr. Ahlers will report to President and Chief Executive Officer S

Most small-cap biotech stocks are pure clinical bets. These three already have revenue on the books and insiders backing them with their own capital.

The head and neck squamous cell carcinoma market is experiencing significant growth, driven by the rising incidence of head and neck cancers worldwide, increasing adoption of immunotherapies, targeted therapies, and combination treatment approaches. Additionally, the expected launch of emerging therapies such as Amivantamab (RYBREVANT) (Johnson & Johnson), BNT113 (BioNTech), CUE-101 (Cue Biopharma), Petosemtamab (MCLA-158) (Genmab), Eftilagimod Alfa (Immutep), and others will further propel the

Physician-scientist and immunology leader joins Cue as the company advances key clinical programs in allergic and autoimmune diseasesBOSTON, July 13, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, today announced the appointment of Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development. He reports to President and Chief Executive Officer Shao-L

BOSTON, July 09, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical stage biopharmaceutical company focused on developing transformative therapies targeting functional cures for immunological disorders, today announced that it has entered into a securities purchase agreement with a group of accredited investors for the private placement of (i) 1,418,071 shares of common stock at a purchase price of $33.21 per share and (ii) to certain investors, in lieu of shares of common st

Daniel Camardo, former CEO and executive commercial leader with a track record of successful launches joins the board Viola Meehan, former CFO with broad experience in governance, strategic finance and executive leadership joins the board BOSTON, June 02, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a precision immuno-engineering company focused on developing transformative therapies targeting functional cures for immunological disorders, today announced the transition of its boar